75125-23-4

Usage

Uses

Used in Pharmaceutical Industry:
(2-Oxo-1,3-oxazolidin-3-yl)acetic acid is used as an intermediate in the synthesis of antibiotics and other pharmaceuticals for its ability to contribute to the development of effective medications.
Used in Chiral Catalysts Production:
It is used in the production of chiral catalysts for its role in facilitating asymmetric reactions, which are crucial for the synthesis of enantiomerically pure compounds.
Used in Organic Synthesis:
(2-Oxo-1,3-oxazolidin-3-yl)acetic acid is used as a building block in organic synthesis for its potential to form complex molecular structures and contribute to the creation of various chemical compounds.
Used in Drug Development:
It has potential applications in the development of new drugs and therapeutic compounds, making it an important compound for research and innovation in the pharmaceutical and chemical industries.

InChI:InChI=1/C5H7NO4/c7-4(8)3-6-1-2-10-5(6)9/h1-3H2,(H,7,8)

Upstream product

• 65538-58-1 N-(2-bromo-ethoxycarbonyl)-glycine methyl ester 
• 75125-24-5 3-ethoxycarbonylmethyl-2-oxazolidinone 
• 3356-88-5 N-(2'-hydroxyethyl)-2-oxazolidone 

Downstream Products

• 1190392-43-8 benzyl (2-oxo-1,3-oxazolidin-3-yl)acetate 
• 1448309-30-5 2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-(N-(3-fluoro-phenyl)-2-(2-oxooxazolidin-3-yl)acetamido)acetamide 
• 1245631-29-1 C₂₆H₃₀N₆O₄ 
• 1190392-45-0 benzyl 2-(2-oxo-1,3-oxazolidin-3-yl)propanoate 

Relevant academic research and scientific papers

PARG INHIBITORY COMPOUNDS

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS

The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. Thesd compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).